Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
NCT01691872
·
clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Development plan of retigabine XR in Japan was readjusted.
Conditions
Epilepsy, Partial
Interventions
DRUG:
Retigabine
Sponsor
GlaxoSmithKline